Sioux Honey and Food City Partner for Record Honey Donation
Johnson City, Tennessee--(Newsfile Corp. - March 12, 2025) - The Sioux Honey Association Co-op is pleased to announce its participation at the Coalition For Kids after-school program alongside a group of about 50 children during in an interactive lesson on honey and honeybee pollination on Wednesday.
The event at the Johnson City nonprofit was part of a broader effort to make a record donation of honey by the Sioux Honey Association Co-op, a beekeeper-owned group of 175+ beekeepers, that was joined by regional grocer Food City to donate 2½ tons of SUE BEE® clover honey to three child-focused organizations: Coalition For Kids; Boys & Girls Clubs of the Tennessee Valley in Knoxville; and Mountain Mission School in Grundy, Va.
The honey will be used as part of meals and snacks for after-school programs, organizers said. The donation of 540 cases (with 6,480 bottles of honey) was divided evenly among the three nonprofits.
'It's a ton of honey - actually about two-and-a-half tons,' said Kevin Hueser, President & CEO of the Sioux Honey Co-op. 'But it will go fast; it should certainly be gone before the three-year expiration date for honey passes.'
On Wednesday, children at Coalition For Kids learned about worker bees, drone bees and queen bees, as well as how honeybees help pollinate everyday foods, such as almonds, melons and avocados.
To demonstrate the pollination process, children played 'honeybees,' with yellow cotton balls while other students portrayed 'flowers' by holding cups filled with different-colored glitter. The children learned how honeybees carry pollen from flower to flower, and how cross-pollination happens as pollens mix.
'It was a fun exercise for our after-school kids,' said Randy Hensley, Executive Director at Coalition For Kids. 'And the honey donation will help with snacks for the kids in our after-school programs.'
Said Chris Mitchell, President at Mountain Mission School: 'As a beekeeper myself, I understand the importance of this process of nature; honeybee pollination is an essential part of the food production process.'
Wednesday's donations to the three child-focused organizations are just one of several donation efforts planned by the Sioux Honey Co-op in 2025. More donations will be coming later this summer following the honey harvest season.
'As beekeepers, we are passionate not only about our honey, but also about giving back to the communities we serve,' said David Coy, a third-generation Sioux Honey Co-op beekeeper whose family tends to beehives in Perkinston, Miss., and Hebron, N.D.
More than 50 students who take part in the Coalition For Kids after-school program in Johnson City, participated Wednesday in an interactive and hands-on lesson about honeybees and how honeybee pollination works. The event was part of a large honey donation made by the Sioux Honey Association Co-op and Food City.
A donation of 2,160 bottles of SUE BEE® honey was made to Coalition For Kids in Johnson City on Wednesday by the Sioux Honey Association Co-op and Food City.
To view an enhanced version of this graphic, please visit:
[ This image cannot be displayed. Please visit the source: ]
To view an enhanced version of this graphic, please visit:
ABOUT SIOUX HONEY: In 1921, the Sioux Honey Co-op began as a small group of just five beekeepers. Located near Sioux City, Iowa, they shared equipment, marketing and processing facilities - all to help support one another. Today, Sioux Honey is still a co-op, but it has grown into 175+ beekeepers nationwide. Some have been members for decades - part of families who have passed down the trade for generations - and some have pioneered and started their own bee farms. But all of the members have a passion for producing a pure, quality product that customers can trust. And we're proud to say we know each of our beekeepers by name, because we've learned that's how you produce the best honey for more than a century.
ABOUT FOOD CITY: Headquartered in Abingdon, Virginia, K-VA-T Food Stores (Food City's parent company) operates 158 retail outlets throughout southeast Kentucky, southwest Virginia, east Tennessee, north Georgia, and Alabama.
402-740-8188
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the 'Company'), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. 'TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our TriNav ® product suite and proprietary PEDD ® platform across a broad range of solid tumor indications,' said Mary Szela, President and CEO of TriSalus. 'We are pleased to reaffirm our full-year revenue growth guidance of 50%, reflecting increasing market penetration within liver-directed therapies. We will continue to invest in clinical data to extend the benefits of our PEDD technology platform to new embolization applications. With a strategic shift toward partnering development of Nelitolimod and an expanded focus on liver-directed therapies and new applications, we are energized by the opportunity to bring our PEDD technology to a wider range of patients which will not only support improved clinical outcomes but also drive deeper physician engagement and commercial momentum, fueling our long-term vision.' Second Quarter 2025 Highlights Generated $11.2 million in net sales, a 52% increase year-over-year, and sequential growth of 22% over the first quarter 2025. Continued strong commercial momentum with expanded use of TriNav ® in liver embolization and continued to further develop new applications in new clinical settings focused on the interventional radiology specialty. Expanded product portfolio with the successful launch of TriNav ® FLX, the latest advancement in Pressure-Enabled Drug Delivery (PEDD). Designed with a more flexible distal tip, TriNav FLX enhances navigability through tortuous vessels—providing an effective solution for physicians previously limited by anatomical barriers to PEDD adoption. Early market response has been strong, with sales surpassing internal projections. Subsequent to the second quarter, the Company simplified its capital structure through the successful completion of an exchange offering of previously issued Series A Preferred stock. Second Quarter 2025 Financial Highlights Revenue, all from the sale of the TriNav system, was $11.2 million for the three months ended June 30, 2025, an increase of 52% compared to the same period in 2024 and 22% sequential growth. Revenue growth was driven primarily by increased selling resources and increased market share. Gross margins were 84% in the second quarter, compared to 88% in the same period of 2024. The year-over-year decline was primarily driven by lower manufacturing efficiency associated with newly launched products, a dynamic we expect to improve as production scales and processes mature over the course of the year. Research and Development (R&D) expenses were approximately $3.9 million, compared to $4.7 million for the same quarter of the prior year. The decline in R&D costs is primarily a result of a decline in clinical trial costs relating to Nelitolimod. Sales and Marketing (S&M) expenses were approximately $7.2 million in the second quarter, compared to $6.0 million for the same quarter of the prior year. The year-over-year increase reflects continued investment in the expansion of our commercial organization. General & Administrative (G&A) expenses were approximately $5.7 million, compared to $4.0 million for the same quarter of the prior year. G&A costs include non-cash stock-based compensation of $1.2 million and $0.7 million, respectively, for the same periods. The increase in G&A costs is primarily a result of professional services related to legal services and audit. Operating losses were $7.3 million, compared to Operating losses of $8.2 million for the same period in 2024. Current reductions in operating losses are due to reduced research and development expenses associated with the ramp-down of Nelitolimod clinical trial spending. Net loss attributable to common stockholders was $9.0 million, compared to $5.1 million for the same period in 2024, primarily due to non-cash adjustments to the fair value of our contingent earnout liability. The basic and diluted loss per share was $0.27, compared to $0.21 for the same period in 2024. As of June 30, 2025, cash and cash equivalents totaled $26.5 million providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026. The non-GAAP measure of adjusted EBITDA is reconciled in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $5.3 million, compared to losses of $6.7 million for the same period in 2024. Currently, reductions in adjusted EBITDA losses are due to increased sales, reduced research and development expenses and increased stock compensation in 2025. Conference Call The Company will host a conference call and webcast today at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the investor relations section of TriSalus' website. A replay will also be available on the website following the event. About TriSalus Life Sciences TriSalus Life Sciences ® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav ® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company's filings with the Securities and Exchange Commission under the heading 'Risk Factors.' All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. TRISALUS LIFE SCIENCES, INC. Condensed Consolidated Balance Sheets (unaudited, in thousands) December 31, 2024 Assets Current assets: Cash and cash equivalents $ 26,490 $ 8,525 Accounts receivable, net 5,571 5,087 Inventory, net 3,807 4,048 Prepaid expenses 2,216 3,009 Total current assets 38,084 20,669 Property and equipment, net 1,711 1,669 Right-of-use assets 1,103 1,210 Other assets 419 423 Total assets $ 41,317 $ 23,971 Liabilities and Stockholders' Deficit Current liabilities: Trade payables $ 1,902 $ 2,274 Accrued liabilities 7,078 7,355 Short-term lease liabilities 123 216 Other current liabilities 221 383 Total current liabilities 9,324 10,228 Long-term debt, net of unamortized discount and debt issuance costs 32,274 22,084 Revenue base redemption liability 358 507 Long-term lease liabilities 1,265 1,329 Contingent earnout liability 7,522 7,401 Warrant and SEPA liabilities 9,997 8,316 Total liabilities 60,740 49,865 Commitments and contingencies Stockholders' deficit: Preferred Stock, Convertible Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 3,594,002 and 3,985,002 shares at June 30, 2025, and December 31, 2024, respectively. — — Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 37,983,259 and 31,279,264 shares at June 30, 2025, and December 31, 2024, respectively. 3 3 Additional paid-in capital 278,786 253,652 Accumulated deficit (298,212 ) (279,549 ) Total stockholders' deficit (19,423 ) (25,894 ) Total liabilities and stockholders' deficit $ 41,317 $ 23,971 Expand Non-GAAP Financial Measure To supplement the financial results presented in accordance with GAAP, TriSalus has also included in this press release non-GAAP adjusted EBITDA, which excludes from net loss, income tax expense, interest expense, interest income, change in fair value of SEPA, warrant and revenue-base redemption liabilities, change in fair value of contingent earn out liability, stock-based compensation expense and depreciation. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. TriSalus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand TriSalus' business. TriSalus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, TriSalus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare TriSalus' results from period to period, and to identify operating trends in TriSalus' business.
Business Wire
5 hours ago
- Business Wire
AdvoCare Honors Richardson ISD Teachers and Staff
RICHARDSON, Texas--(BUSINESS WIRE)-- AdvoCare International, LLC, a health and wellness e-commerce company, once again celebrated the educators across three campuses within Richardson ISD (RISD) during Teacher Appreciation Week. AdvoCare donated a total of $3,000 to three schools within RISD – Forest Meadow Middle School, Spring Creek Elementary, and Lake Highlands High School. 'Supporting our local community is one of our core values, and we welcome the chance to pay tribute to our incredible educators and staff each year during this time,' said Christina Helwig, CEO of AdvoCare. Share 'Supporting our local community is one of our core values, and we welcome the chance to pay tribute to our incredible educators and staff each year during this time,' said Christina Helwig, CEO of AdvoCare. 'This is just one way to express our heartfelt gratitude for all they do to shape the hearts and minds of our future generations. We hope our gifts make them feel loved and appreciated for all they give.' As part of the celebration, AdvoCare set up on-site Spark® and AdvoCare Rehydrate® fountains in the teacher's lounge of each school, filling up their cups and giving away gift bags that included sample packs of Spark® and Rehydrate®. They also held a raffle, giving teachers a chance to win more AdvoCare products, gift cards, and a CalPak insulated tote. AdvoCare International, LLC: AdvoCare International, LLC is making pursuing wellness easy and accessible. As an established health and wellness consumer packaged goods company, AdvoCare serves health-aware consumers through products that offer whole body support focusing on energy, hydration, immunity and gut health. Since 1993, AdvoCare has offered trusted health and wellness products like Spark ® to millions of customers and athletes across the world.
Business Upturn
6 hours ago
- Business Upturn
Mellow Sleep Redefines Comfort with a Revolutionary New Cloud Pillow
Dover, Aug. 12, 2025 (GLOBE NEWSWIRE) — DOVER, DE – August 11, 2025 – Mellow Sleep, a leader in sleep ergonomics and material science, today announced the launch of a revolutionary new cloud pillow designed to permanently solve the universal problem of restless, unfulfilling sleep. This launch marks a new era for sleep wellness, moving beyond one-size-fits-all solutions to offer a truly personalized and restorative experience. The frustrating, nightly search for a pillow that is 'just right' is finally over. Millions of people struggle with pillows that are too firm, too soft, too high, or too low, leading to neck pain, shoulder stiffness, and persistent fatigue. This nightly battle for comfort often involves folding, bunching, or stacking pillows in a desperate attempt to find support. Mellow Sleep addresses this issue at its core with a groundbreaking cloud pillow that intelligently adapts to the sleeper. This innovative pillow solves sleep discomfort through its proprietary 3-zone contour design. Each zone is meticulously engineered for a distinct biomechanical purpose. The central contour cradles the head with gentle, pressure-relieving support, while the raised outer edges are optimized for side sleepers, filling the gap between the shoulder and neck. The third zone provides a specialized cervical ramp that delivers a targeted lift, ensuring the spine maintains a natural and healthy alignment throughout the night. This integrated system prevents the awkward angles that lead to morning aches and pains. 'Our goal was to create the perfect cloud pillow by listening to the real-world frustrations of sleepers,' said Jay Yue, founder of Mellow Sleep. 'People are tired of compromising. They shouldn't have to choose between a soft feel and firm support. We spent years researching materials and ergonomics to find a way to deliver both. The result is our new CloudAlign™ Pillow, a product we believe sets a new industry standard for what a pillow can and should do for your well-being. It's more than just a place to rest your head; it's an investment in your health.' At the heart of this exceptional Mellow Sleep cloud pillow is the CloudSoft Core™, a proprietary shape-retaining memory foam. Unlike conventional foams that can be slow to respond or lose shape, the CloudSoft Core™ offers dynamic, flexible support that adapts instantly to every micro-movement. This ensures consistent comfort and alignment, whether you are a back, side, or combination sleeper. The exterior is just as thoughtfully designed. The pillow is encased in a removable, OEKO-TEX® Certified cover. This certification guarantees the fabric is free from harmful chemicals, making it hypoallergenic, breathable, and exceptionally gentle on the skin. Further enhancing its superior adaptability, the pillow features a SwitchFit™ design. This innovative feature gives users dual-height support, allowing them to simply flip the pillow to choose between a lower and a higher profile to perfectly match their body frame and sleep preference. For lasting hygiene, all materials are fast-drying and easily washable. This new Mellow Sleep cloud pillow from Mellow Sleep is now available for purchase directly from the company's website: offering an end to compromise and a new beginning for deep, restorative sleep. About Mellow Sleep: Mellow Sleep is a forward-thinking company dedicated to advancing human well-being through the science of sleep. By focusing on biomechanics, certified non-toxic materials, and user-centric design, Mellow Sleep creates innovative products that provide tangible improvements to sleep health. Their mission is to engineer a better night's sleep for a better life. Media Contact: [email protected] ### For more information about Mellow LLC, contact the company here: Mellow LLCJay Yue9293555134 [email protected] 8 The Green, Dover, DE 19901
